Results 1 to 10 of about 859,888 (229)

Real‐World Experience in Tricuspid Transcatheter Edge‐to‐Edge Repair: Transcatheter Tricuspid Valve Repair in Spain Registry [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Significant tricuspid regurgitation (TR) is associated with increased morbidity and mortality. The development of transcatheter valve repair therapies has opened a wide range of opportunities for treatment of patients with high surgical risk ...
Antonio Sisinni, Manuel Barreiro‐Perez, Xavier Freixa, Dabit Arzamendi, Vanessa Moñivas, Fernando Carrasco‐Chinchilla, Manuel Pan, Luis Nombela‐Franco, Isaac Pascual, Tomás Benito‐González, Ruth Perez, Iván Gómez‐Blázquez, Ignacio J. Amat‐Santos, Ignacio Cruz‐González, Ángel Sánchez‐Recalde, Ana Belén Cid Alvarez, Laura Sanchis, Berenice Caneiro‐Queija, Chi Hion Li, Maria del Trigo, Jose David Martínez‐Carmona, Dolores Mesa, Eduardo Pozo, Pablo Avanzas, Pedro Cepas‐Guillén, Rodrigo Estévez‐Loureiro   +25 more
doaj   +7 more sources

1-Year Outcomes of Transcatheter Tricuspid Valve Repair.

Journal of the American College of Cardiology, 2023
BACKGROUND Surgical management of isolated tricuspid regurgitation (TR) is associated with high morbidity and mortality, thereby creating a significant need for a lower-risk transcatheter solution.
Rebecca T. Hahn, Moody Makar, Dale Fowler   +2 more
exaly   +4 more sources

Multimodality imaging for transcatheter tricuspid valve repair and replacement. [PDF]

Front Cardiovasc Med, 2023
Transcatheter tricuspid intervention is a rapidly evolving field with multiple classes of therapeutic devices currently in development. Procedural success in tricuspid intervention is predicated on appropriate device selection for patient specific ...
Tomlinson S, Rivas CG, Agarwal V, Lebehn M, Hahn RT.   +4 more
europepmc   +5 more sources

Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis [PDF]

ESC Heart Failure, 2023
Aims Wildtype transthyretin amyloid cardiomyopathy is an under‐recognized cause of heart failure in elderly patients. Transcatheter tricuspid valve repair is a newly emerging therapeutic option for severe tricuspid regurgitation (TR).
Isabel A. Hoerbrand, Martin J. Volz, Fabian Aus dem Siepen, Matthias Aurich, Philipp Schlegel, Nicolas A. Geis, Ute Hegenbart, Mathias H. Konstandin, Norbert Frey, Philip W. Raake   +9 more
doaj   +2 more sources

Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair.

Journal of the American College of Cardiology, 2022
BACKGROUND The right ventricular (RV)-pulmonary arterial (PA) coupling ratio relates the efficiency with which RV stroke work is transferred into the PA. Lower ratios indicate an inadequate RV contractile response to increased afterload.
Fabien Praz, Rodrigo Estévez-Loureiro, Hans-Josef Feistritzer   +2 more
exaly   +2 more sources

C-reactive protein-to-albumin ratio is associated with mortality after transcatheter tricuspid valve repair. [PDF]

Clin Res Cardiol
Transcatheter tricuspid valve repair (TTVr) is a treatment option for tricuspid regurgitation (TR) in patients with high surgical risk. Given the heterogeneity in clinical benefit, there is a need for markers to assess mortality risk in patients ...
Finke K, Marx L, Althoff J, Gietzen T, Schäfer M, Wrobel J, von Stein P, von Stein J, Körber MI, Baldus S, Pfister R, Iliadis C.   +11 more
europepmc   +2 more sources

Association between psoas muscle area and outcomes after transcatheter tricuspid valve repair. [PDF]

Cardiovasc Interv Ther
Transcatheter tricuspid valve repair (TTVR) might be an alternative option to reduce tricuspid regurgitation (TR) in patients with sarcopenia. Psoas muscle area (PMA) measured using computed tomography (CT) is known as a marker of sarcopenia.
Balata M, Tanaka T, Sugiura A, Kavsur R, Vogelhuber J, Öztürk C, Zimmer S, Luetkens J, Nickenig G, Weber M.   +9 more
europepmc   +2 more sources

Quality of life after transcatheter tricuspid valve repair: results from the Tri.FR trial. [PDF]

ESC Heart Fail
In the Tri.FR trial, tricuspid transcatheter edge‐to‐edge repair (T‐TEER) reduced severity of tricuspid regurgitation (TR) and improved the composite clinical score, driven by patient‐reported outcomes.
Istratoaie S, de Groote P, Karam N, Trochu JN, Leurent G, Coisne A, Le Roux PY, Ganivet A, Bernard A, Neylon A, Pierrard R, Le Ven F, Picard F, Piriou N, Laperche T, Jouan J, Anselmi A, Auffret V, Oger E, Donal E.   +19 more
europepmc   +2 more sources

Right-Sided Infective Endocarditis After Edge-to-Edge Transcatheter Tricuspid Valve Repair. [PDF]

JACC Case Rep
Background Tricuspid transcatheter edge-to-edge repair (T-TEER) is an emerging treatment option in symptomatic patients with severe tricuspid regurgitation (TR) and high surgical risk. TEER devices can become infected.
Polo JCG, Vilacosta I, García Martí G, Ortiz Lozada R, Playán Escribano J, Mahia P, Jiménez Quevedo P, Nombela L, Casado I.   +8 more
europepmc   +2 more sources

Predictive value of CT-based and AI-reconstructed 3D-TAPSE in patients undergoing transcatheter tricuspid valve repair. [PDF]

Front Cardiovasc Med
Background The tricuspid annular plane systolic excursion (TAPSE) assessed by echocardiography has failed in predicting outcomes in patients with severe tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI ...
Kirchner J, Gerçek M, Omran H, Friedrichs KP, Rudolph F, Rossnagel T, Piran M, Goncharov A, Ivannikova M, Rudolph V, Rudolph TK.   +10 more
europepmc   +2 more sources